MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis

Zhong, Chenming; Xie, Zijun; Zeng, Ling‐Hui; Yuan, Chunhui; Duan, Shiwei

doi:10.3389/fimmu.2022.855078

Cited by 32 publications

(28 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prognostic biomarkers can guide individualized treatment, assess efficacy, and optimize follow-up ( 35 ). Several prognostic biomarkers have been discovered, such as CA19-9 ( 36 ), MIR4435-2HG ( 37 ), AFP ( 38 ), and CEA ( 39 ). In recent years, with the development of technology, especially the advent of liquid biopsy ( 40 ), circulating tumor DNA (ctDNA) has become a new biomarker for the diagnosis of cancer ( 41 , 42 ).…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIt has been reported that ING3 inhibits the progression of various cancers. However, some studies have shown that it promotes the development of prostate cancer. The purpose of this study was to investigate whether ING3 expression is associated with the prognosis of patients with cancer.Materials and methodsPubMed, Cochrane Database, Embase, Medline, ScienceDirect, Scopus and Web of Science were searched until September 2022. The hazard ratio (HR)/odds ratio (OR) and 95% confidence interval (95% CI) were calculated using Stata 17 software. We used the Newcastle-Ottawa Scale (NOS) to assess the risk of bias.ResultSeven studies involving 2371 patients with five types of cancer were included. The results showed that high expression of ING3 was negatively associated with a more advanced TNM stage (III-IV vs. I-II) (OR=0.61, 95% CI: 0.43-0.86), lymph node metastasis (OR=0.67, 95% CI: 0.49-0.90) and disease-free survival (HR=0.63, 95% CI: 0.37-0.88). However, ING3 expression was not associated with overall survival (HR=0.77, 95% CI: 0.41-1.12), tumor size (OR=0.67, 95% CI: 0.33-1.37), tumor differentiation (OR=0.86, 95% CI: 0.36-2.09) and gender (OR=1.14, 95% CI: 0.78-1.66).ConclusionThis study showed that the expression of ING3 was associated with better prognosis, suggesting that ING3 may be a potential biomarker for cancer prognosis.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier (CRD42022306354).

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Chen

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Hence, optimizing treatment outcomes for any disease is only possible with full knowledge of the underlying mechanisms. In this regard, recent studies involving lncRNAs have substantially contributed to understanding the cancer (Li et al, 2022b;Singh et al, 2022;Zhong et al, 2022). However, exploiting the potential of lncRNAs as biomarkers and therapeutic targets is just the beginning (Mirzaei et al, 2022).…”

Section: Therapeutic Importance Of Lncrna Linc-pintmentioning

confidence: 99%

Clinical implications of lncRNA LINC-PINT in cancer

Bukhari

Khan

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.

show abstract

“…Competitive endogenous RNAs (ceRNAs) such as long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) can compete with miRNAs [3], and thus regulate the expression of miRNAs and their targeted inhibition of protein-coding genes [4]. There are at least 19 target genes of miR-1294.…”

Section: Introductionmentioning

confidence: 99%

The tumor suppressor role and ceRNA network of miR-1294 in cancer

Mao¹,

Shen²,

FANG³

et al. 2023

Oncology Research

Self Cite

View full text Add to dashboard Cite

miRNAs are endogenous small RNAs that are important regulators of gene expression. miR-1294 was found to be significantly down-regulated in 15 cancers and regulated by 21 upstream regulators. miR-1294 affects the proliferation, migration, invasion, and apoptosis of cancer cells. The target genes of miR-1294 are involved in the PI3K/AKT/mTOR, RAS, and JAK/STAT signaling pathways. Six target genes of miR-1294 are the targets of a variety of drugs. Low expression of miR-1294 is associated with resistance to cisplatin and TMZ and a poorer prognosis in patients with ESCC, GC, EOC, PDAC, or NSCLC. Therefore, this work outlines the molecular mechanisms and provides a basis for the clinical significance of the tumor suppressor miR-1294 in cancer.

show abstract

MIR4435-2HG Is a Potential Pan-Cancer Biomarker for Diagnosis and Prognosis

Cited by 32 publications

References 66 publications

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis

Clinical implications of lncRNA LINC-PINT in cancer

The tumor suppressor role and ceRNA network of miR-1294 in cancer

Contact Info

Product

Resources

About